Comparative Pharmacology
Head-to-head clinical analysis: GENTACIDIN versus LOTEPREDNOL ETABONATE AND TOBRAMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENTACIDIN versus LOTEPREDNOL ETABONATE AND TOBRAMYCIN.
GENTACIDIN vs LOTEPREDNOL ETABONATE AND TOBRAMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis.
Loteprednol etabonate is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis; tobramycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis.
5-7 mg/kg IV every 24 hours.
1-2 drops into affected eye(s) every 4-6 hours; in severe cases, may be given every 1-2 hours initially.
None Documented
None Documented
2-3 hours in adults with normal renal function; extended to 24-48 hours in anuria or severe renal impairment, requiring dose adjustment.
Loteprednol etabonate: ~2.8 hours (ocular); Tobramycin: ~2-3 hours (systemic, prolonged in renal impairment)
Renal: 95-98% unchanged via glomerular filtration; biliary/fecal: <2%.
Loteprednol etabonate: 75% renal, 20% fecal; Tobramycin: >90% renal as unchanged drug via glomerular filtration
Category C
Category D/X
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic